Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which
translates to variable response to treatment and outcome. With the recent increase in …

Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago
remain major prognostic factors. In recent years, the introduction of cutting-edge genomic …

Purpose The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and
reliable tool is needed to stratify patients with MM. We combined the International Staging …

Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …

Purpose At the molecular level, myeloma is characterized by copy number abnormalities
and recurrent translocations into the immunoglobulin heavy chain locus. Novel methods …

Therapy for multiple myeloma (MM) has markedly changed in the past decade with the
introduction of new drugs, but it is not clear whether the improvements have been sustained …

Risk stratification in multiple myeloma is important for prognostication, patient selection for
clinical trials, and comparison of treatment approaches. We developed and validated a …

Exosomes, secreted by several cell types, including cancer cells, can be isolated from the
peripheral blood and have been shown to be powerful markers of disease progression in …

PURPOSE The GMMG-CONCEPT trial investigated isatuximab, carfilzomib, lenalidomide,
and dexamethasone (Isa-KRd) in transplant-eligible (TE) and transplant-noneligible (TNE) …

With growing numbers of elderly multiple myeloma patients, reliable tools to assess their
vulnerability are required. The objective of the analysis herein was to develop and validate …